Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Status:
Completed
Trial end date:
2009-05-09
Target enrollment:
Participant gender:
Summary
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast
(20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic
arthritis.